Chemical denaturation is becoming increasingly popular in the drug development process. On one hand, it allows for determining the free enthalpy (ΔG) of unfolding of monoclonal antibodies (mAbs), which directly correlates with the fraction of unfolded protein in solution and provides thermodynamic insight into mAb stability. On the other hand, it is a tool to predict the aggregation propensity and aggregation mechanism of mAbs. Chemical denaturation experiments are performed by measuring the fraction of unfolded protein (e.g. by measuring the F350/F330 ratio) in a gradient of denaturant concentrations. Common denaturants are 0-8 M GuaHCl, 0-10 M Urea. In order to record a sufficient number of data points for fitting, at least 24 different denaturant concentrations should be measured. In order to derive correct ΔG values from chemical denaturation experiments, it is of major importance to use fully equilibrated samples. The time required for full equilibration is however often unknown, and some of the current commercial instrument solutions to detect chemical unfolding combine sample preparation and detection, which might lead to unsufficient incubation times.
Have a question about Prometheus?
Contact SpecialistSee more related content

In this webinar Dr. Melanie McDowell, Research Group Leader at the MPI of Biophysics outlines bottlenecks associated with membrane protein purification for cryo EM and strategies to overcome them

When working with membrane proteins, whether you’re troubleshooting aggregation, testing new solubilization strategies, or deciding when to switch detergents read this guide for practical solutions.

Learn about Prometheus Panta C: A next-generation stability characterization platform that's helping biomanufacturers bring automation into the analytical core of their development and process control

Dr. Marius Müller of Johnson & Johnson Innovative Medicine shares insights from questions about the use of nanoDSF™ technology for ID-testing and at several late stages of biotherapeutics development.

Explore a comprehensive, data-driven workflow—rooted in real-world results—combining the NativeMP platform with Prometheus Panta.

NanoTemper Technologies announces the launch of Prometheus Panta C, a solution designed to meet the evolving needs of biopharmaceutical development—from preclinical phase to commercial manufacturing.

Learn how to enhance your lab's efficiency with Prometheus Panta, from using capillary chips for high-throughput sample loading to solutions for seamless integration in automated workflows

Expert Marius Müller, PhD, Team Lead at Johnson & Johnson Innovative Medicine, shares insights into three significant trends that have potential to reshape the biopharma and biomanufacturing industry

Increase your throughput, improve precision, and streamline your workflow by automating biologics characterization. Discover Prometheus Panta, an instrument for multi-parameter stability measurements

Watch this webinar to discover how Dr. Marius Müller from Johnson & Johnson Innovative Medicine, uses nanoDSF, a high-throughput method that assesses protein stability, for drug substance ID testing.

Use this curated list of must-attend 2025 biologics conferences to plan your year. Find out when and where each conference takes place, who will be there, and what you can expect.

Learn about technologies and instruments that maintain membrane protein stability and allow structural abd affinity screening studies in their natural lipid environment.

Watch this webinar about approaches and insights into bispecific formulation development and screening with Prometheus Panta for thermal and colloidal stability characterization of biotherapeutics.

Learn how Pierre Fabre uses multi-parameter stability measurements of mAb libraries on Prometheus Panta to streamline developability platforms, reducing complexity, cost, and sample consumption.

Membrane proteins present challenges for structural analysis by cryo-EM; Screening of synthetic copolymers with nanoDSF and DLS on Prometheus Panta help select the best solubilization conditions.

Read why scientist Dr. Elsa Wagner chose the Prometheus Panta instrument with simultaneous measurements of DLS, nanoDSF, SLS and backreflection for developability assessment of their mAbs candidates.

The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics

Your protein stability characterization projects require tools that provide high-precision, high-quality data to support your selection process. Watch this 10 min walkthrough of Prometheus Panta.

Get developability profiles for monoclonal antibodies with stability data from Prometheus Panta to inform on rational design and selection of therapeutic constructs that will succeed in the clinic.